Chi Yan
7PUBLICATIONS
10CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jan 12, 2026
RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b<sup>+</sup> Bregs thereby overcoming melanoma PD1-resistance.Chi Yan, Weifeng Luo, Jinming Yang
|Jul 29, 2023
Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma.Chi Yan, Caroline A Nebhan, Nabil Saleh
|Jul 09, 2022
Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.Zhizhu Zhang, Ann Richmond, Chi Yan
|Jan 21, 2022
Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients.Chi Yan, Sheau-Chiann Chen, Gregory D Ayers
|Jun 02, 2021
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.Chi Yan, Jinming Yang, Nabil Saleh
|Nov 12, 2020
Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.Jinming Yang, Chi Yan, Anna E Vilgelm
Pageof 2
Frequent Collaborators
6 joint publications
Ann Richmond
2 joint publications
Nabil Saleh
1 joint publications
Jun Wang
1 joint publications
Sheau-Chiann Chen
1 joint publications
Christopher A Johnson
1 joint publications
Vandana G Abramson
1 joint publications
Anna E Vilgelm
1 joint publications
Vivian L Weiss
1 joint publications
Douglas B Johnson
1 joint publications
Qi Liu
